Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of calcineurin inhibitors in renal transplantation.

Transplantation - 15 Aug 2009

Coto Eliecer, Tavira Beatriz

Abstract excerpt

Cyclosporine A and tacrolimus (Tac) are inmunosuppresive drugs with a narrow therapeutic range. Underdosing is associated with organ rejection, whereas overdosing could result in toxicity. Therapeutic drug monitoring at different postdose times is necessary to maintain the blood concentrations within a target window. These calcineurin inhibitors are characterized by a broad interindividual pharmacokinetics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alternative Splicing
Share to Calcineurin Inhibitors
Share to Cyclosporine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Pharmacogenetics

Share to Tacrolimus

Source

Identifiers

PMID: 19667964
DOI: 10.1097/TP.0b013e3181afe9e7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of calcineurin inhibitors in renal transplantation.PMID 19667964Read ↗

Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.Semantic proximity Read ↗

The Pharmacogenetics of Calcineurin Inhibitors: One Step Closer Toward Individualized Immunosuppression?Semantic proximity Read ↗

Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.Semantic proximity Read ↗

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Semantic proximity Read ↗

Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Semantic proximity Read ↗

CYP3A5 Polymorphisms Leading to Tacrolimus Toxicity Following an Adult Renal Transplant.Semantic proximity Read ↗

Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients.Semantic proximity Read ↗

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.Semantic proximity Read ↗

The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Semantic proximity Read ↗

Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipientsSemantic proximity Read ↗

Impact of CYP3A5 1* and 3* single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patientsSemantic proximity Read ↗

Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.